Inivata Launches RaDaR™ Assay for Detection of Residual Disease and Recurrence
Personalized multi-tumor test provides potential new option for the rapid and sensitive identification of
residual disease and clinical relapse
Initial application in pharmaceutical clinical trial settings
Research Triangle Park, NC, USA and Cambridge, UK, 23 April, 2020 -- Inivata, a leader in liquid biopsy announces the availability of RaDaR™, an assay for the detection and monitoring of residual disease and recurrence in the plasma samples of patients previously diagnosed with cancer. RaDaR is designed to be complementary to tumor profiling assays including Inivata’s InVisionFirst®-Lung and will initially be used in a clinical trial setting for patients who have already received a cancer diagnosis.
The RaDaR assay is built on Inivata’s proven InVision® liquid biopsy platform technology. This next-generation sequencing platform incorporates built-in controls and error-correction for highly sensitive and specific variant detection. RaDaR is a personalized assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, allowing both detection of residual disease following curative intent or definitive treatment, and early detection of relapse. With a turnaround time of seven calendar days for monitoring, RaDaR will be added to the range of assays offered through Inivata’s CAP/ CLIA lab.
Initial applications for RaDaR will be in clinical research. The availability of an assay with a level of sensitivity that exceeds current fixed panel approaches will allow accurate patient selection for enriched clinical trial populations. This specific patient selection approach may allow for more focused clinical trials with faster recruitment rates. In addition, the ability to track therapeutic treatment success through accurate liquid biopsy will allow earlier visibility of drug efficacy.
Clive Morris, Chief Executive Officer of Inivata, commented: “RaDaR is a highly sensitive, personalized test which will allow for the detection of residual disease in multiple tumor types, providing uniquely valuable insights into a patient’s disease state. This information can be used to speed recruitment into clinical trials with a more accurate selection of eligible patients, whilst driving efficiency of the trials themselves. We look forward to applying our technology through partnerships with pharmaceutical companies and to bringing its benefits to patients.”
About Inivata
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Angela Gray/Sarah Wilson
Paul Rabin (US)
inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271
Karen Chandler-Smith
karen.chandler-smith@inivata.com +44 (0)7900 430235